Abstract 308P
Background
We investigated the landscape of clinically relevant mutations in ctDNA from NSCLC patients in East Asia tested by a commercially available comprehensive next generation sequencing (NGS) assay (Guardant360) as part of clinical practice. This assay identifies single nucleotide variants (SNV), insertions (ins) and deletions (del), fusions, and amplifications (amp), with complete exon sequencing of multiple genes including EGFR, ERBB2, and KRAS.
Methods
Test results from Hong Kong, Korea, Taiwan, Japan and Southeast Asia were reviewed (cut-off June 2020). We identified cases with a diagnosis of “lung cancer,” excluding neuroendocrine, sarcomatoid, and pure squamous histology. Samples from patients enrolled in prospective clinical trials were excluded. Clinically relevant biomarkers were mutations in EGFR, ERBB2, or KRAS; BRAF V600E; MET amp or exon 14 skipping; and ALK, ROS1, RET, or NTRK1 fusions. Synonymous mutations and variants of unknown significance were not considered.
Results
Plasma from 1219 advanced non-squamous NSCLC patients was tested. Samples came from 663 women and 556 men, median age 62 years. Median turnaround time was 7 days from sample receipt to report. ctDNA was identified in 1034 samples (85% detection rate), with median variant allele fraction 0.6%. There were 718 samples (69%) with alterations in at least one clinically relevant biomarker: EGFR (49%), KRAS (8%), ERBB2 (4%), ALK (3%), RET (2%), MET (2%), BRAF (1%), and ROS1 (<1%). Co-mutations were detected in <1%. Potentially actionable EGFR alterations other than L858R or exon 19 del were found in 106 samples (13%), including exon 19 ins (1); exon 20 ins (25); and activating SNV (80) such as L718X (14), L861Q (7), G719A (7), and E709A (5). KRAS G12C was present in 22 samples (2%).
Conclusions
In the clinical practice setting, comprehensive NGS detected relevant biomarkers in 69% of plasma samples with ctDNA from patients with advanced non-squamous NSCLC. Using a single assay, both common and rare driver mutations could be found in a timely manner, obviating the need for multiple tests to identify less common actionable alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guardant Health AMEA.
Funding
Has not received any funding.
Disclosure
B.C. Cho: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (self): Bayer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): MOGAM Institute; Honoraria (self), Research grant/Funding (institution): Dong-A ST; Honoraria (self), Research grant/Funding (institution), Licensing/Royalties: Champions Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Janssen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Yuhan; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Ono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy, Research grant/Funding (institution): Medpacto; Advisory/Consultancy, Research grant/Funding (institution): Eli Lilly; Advisory/Consultancy, Research grant/Funding (institution): Blueprint Medicines; Advisory/Consultancy: Boehringer-Ingelheim; Advisory/Consultancy: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: Pfizer; Honoraria (self): Guardant Health AMEA; Advisory/Consultancy: Takeda; Research grant/Funding (institution): AbbVie. H.H.F. Loong: Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer-Ingelheim; Advisory/Consultancy: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli-Lilly; Advisory/Consultancy: Illumina; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Takeda; Speaker Bureau/Expert testimony: AbbVie; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bayer; Speaker Bureau/Expert testimony: Eisai; Speaker Bureau/Expert testimony: Guardant Health; Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (institution): Mundipharma. H.R. Kim: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Roche. M. Lee: Full/Part-time employment: Guardant Health AMEA. S. Olsen: Full/Part-time employment: Guardant Health AMEA; Shareholder/Stockholder/Stock options: Guardant Health, Inc.; Shareholder/Stockholder/Stock options: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session
286P - Improved diagnostic accuracy on MR imaging in post-surgical recurrent head and neck SCC lesions using decision tree classification system
Presenter: Ankush Jajodia
Session: e-Poster Display Session
287P - Establishment of nasopharyngeal carcinoma organoid culture system and preliminary exploration of drug sensitivity test in vitro
Presenter: Wang Wen
Session: e-Poster Display Session
288P - Application of volumetric modulated arc therapy (VMAT) in head and neck cancers: 5-year single institutional experience
Presenter: Hiep Doan
Session: e-Poster Display Session
289P - Radiotherapy in advanced nasopharyngeal carcinoma
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
292P - Shared decision-making at the cancer institute adult outpatient clinics of a tertiary hospital in the Philippines: A cross sectional study
Presenter: Marvin Jonne Mendoza
Session: e-Poster Display Session
293P - Prolonged release (PR) oxycodone/naloxone (OXN) for cancer pain (CP) & its impact on bowel function, safety & quality of life (QoL): Systematic review
Presenter: Sam Hjelmeland Ahmedzai
Session: e-Poster Display Session
294P - Interventional pain treatment in patients with pain syndrome in advanced tumours of small pelvis
Presenter: Yakhyo Ziyaev
Session: e-Poster Display Session
295P - Assessment of the impact of palliative care on the quality of life in advanced non-small cell lung cancer patients
Presenter: Sabin Katpattil
Session: e-Poster Display Session
296P - Outcomes of repeat transhepatic percutaneous biliary drainage in patients presenting with recurrent malignant biliary stricture
Presenter: Deevia Hanji
Session: e-Poster Display Session